menu
    • menu
    [{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tarlige\u00ae Tablets Approved in Japan for Treatment of Patients with Neuropathic Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2022","year":"2022","type":"Not Applicable","leadProduct":"Mirogabalin Besylate","moa":"CaV1\/CaV2 Channel","url1":"","url2":"","graph1":"Neurology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for ((1R,5S,6S)-6-(AMINOMETHYL)-3-ETHYLBICYCLO(3.2.0)HEPT-3-EN-6-YL)ACETIC ACID MONOBENZENESULFONATE

    Menu

    ((1R,5S,6S)-6-(AMINOMETHYL)-3-ETHYLBICYCLO(3.2.0)HEPT-3-EN-6-YL)ACETIC ACID MONOBENZENESULFONATE

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Daiichi Sankyo

                            Japan arrow
                            Discovery on Target
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mirogabalin Besylate

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tarlige® Tablets Approved in Japan for Treatment of Patients with Neuropathic Pain

                            Details : Tarlige® (mirogabalin besilate), is an analgesic works by inhibiting the excessive release of pain-related neurotransmitters in presynaptic nerve terminal, ® was approved for the indication of “peripheral neuropathic pain” in Japan.

                            Brand Name : Tarlige

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 28, 2022

                            Lead Product(s) : Mirogabalin Besylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth